|
Click on link to view section or document |
|
1. Entire Document including Exhibit(s)
|
| 2. S-1/A
|
| PAGE: 1 - (cover continued from previous page) |
| PAGE: 2 - The information contained in this prospectus is not complete and may be changed. We may not sell the |
| PAGE: 3 - TABLE OF CONTENTS |
| PAGE: 4 - PROSPECTUS SUMMARY |
| PAGE: 5 - Duromist |
| PAGE: 6 - Going Concern and Management s Plan |
| PAGE: 7 - SUMMARY OF THE OFFERING |
| PAGE: 8 - SUMMARY OF SELECTED FINANCIAL INFORMATION |
| PAGE: 9 - RISK FACTORS |
| PAGE: 10 - We will require significant capital for product development and commercialization in the near term. |
| PAGE: 11 - We are a pre-commercialization company, have a limited operating history and have not generated any |
| PAGE: 12 - Our technology platform is based solely on our proprietary drug delivery technology. Our ongoing cli |
| PAGE: 13 - Our business and revenue is dependent on the successful development of our products. |
| PAGE: 14 - We must comply with current Good Manufacturing Practices. |
| PAGE: 15 - Failure to achieve and maintain effective internal controls in accordance with Section 404 of the Sa |
| PAGE: 16 - Limited product liability insurance coverage may affect our business. |
| PAGE: 17 - The clinical trial and regulatory approval process for our products is expensive and time consuming, |
| PAGE: 18 - We expect to face uncertainty over reimbursement and healthcare reform. |
| PAGE: 19 - If we cannot protect our intellectual property, other companies could use our technology in competit |
| PAGE: 20 - Even if we obtain patents to protect our products, those patents may not be sufficiently broad and o |
| PAGE: 21 - If we cannot meet requirements under our license agreements, we could lose the rights to our product |
| PAGE: 22 - Risk Related to Our Common Stock |
| PAGE: 23 - Because the average daily trading volume of our common stock is low, the ability to sell our shares |
| PAGE: 24 - Additional authorized shares of our common stock and preferred stock available for issuance may adve |
| PAGE: 25 - Shares eligible for future sale may adversely affect the market. |
| PAGE: 26 - Sales of large quantities of our common stock by our stockholders, including those shares issued in |
| PAGE: 27 - We may be obligated, under certain circumstances, to pay liquidated damages to holders of our common |
| PAGE: 28 - SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS |
| PAGE: 29 - USE OF PROCEEDS |
| PAGE: 30 - CAPITALIZATION |
| PAGE: 31 - DESCRIPTION OF BUSINESS |
| PAGE: 32 - Zolpimist |
| PAGE: 33 - Zensana |
| PAGE: 34 - Our Business Strategy |
| PAGE: 35 - Agreement with Par Pharmaceutical, Inc. and Hana BioSciences, Inc. |
| PAGE: 36 - Agreement with Velcera Pharmaceuticals, Inc. |
| PAGE: 37 - Manufacturing |
| PAGE: 38 - Patents and Protection of Proprietary Information |
| PAGE: 39 - Buccal Nonpolar Sprays |
| PAGE: 40 - Buccal Nonpolar Spray for Nitroglycerin |
| PAGE: 41 - |
| PAGE: 42 - Stable Hydroalcoholic Oral Spray Formulations and Methods |
| PAGE: 43 - Anti-Insomnia Compositions and Methods |
| PAGE: 44 - |
| PAGE: 45 - The Hatch-Waxman Act |
| PAGE: 46 - Section 505(b)(2) New Drug Applications |
| PAGE: 47 - Anti-Kickback, False Claims Laws The Prescription Drug Marketing Act |
| PAGE: 48 - MANAGEMENT |
| PAGE: 49 - Steven B. Ratoff |
| PAGE: 50 - LEGAL PROCEEDINGS |
| PAGE: 51 - PRICE RANGE OF COMMON STOCK |
| PAGE: 52 - SELECTED FINANCIAL INFORMATION |
| PAGE: 53 - |
| PAGE: 54 - SUPPLEMENTARY FINANCIAL INFORMATION |
| PAGE: 55 - MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND |
| PAGE: 56 - Duromist |
| PAGE: 57 - NVD-201 |
| PAGE: 58 - Results of Operations |
| PAGE: 59 - |
| PAGE: 60 - Years Ended December 31, 2008 and December 31, 2007 |
| PAGE: 61 - |
| PAGE: 62 - Liquidity and Capital Resources |
| PAGE: 63 - Contractual Obligations |
| PAGE: 64 - Warrants Issued with Financing |
| PAGE: 65 - DIRECTORS AND NAMED EXECUTIVE OFFICERS |
| PAGE: 66 - Steven B. Ratoff |
| PAGE: 67 - Charles Nemeroff, M.D., Ph.D. |
| PAGE: 68 - Joseph M. Warusz |
| PAGE: 69 - Setting Executive Compensation |
| PAGE: 70 - Components of Compensation |
| PAGE: 71 - Base Salary |
| PAGE: 72 - |
| PAGE: 73 - Fiscal Year 2010 Bonus Information and 2011 Targets |
| PAGE: 74 - Stock Options. |
| PAGE: 75 - Severance and Change in Control Arrangements |
| PAGE: 76 - Summary Compensation Table |
| PAGE: 77 - All Other Compensation 2010 |
| PAGE: 78 - Outstanding Equity Awards at Fiscal Year-End |
| PAGE: 79 - Option Exercises and Stock Vested During 2010 |
| PAGE: 80 - Employment Agreements |
| PAGE: 81 - Steven B. Ratoff. |
| PAGE: 82 - Craig A. Johnson. |
| PAGE: 83 - DIRECTOR COMPENSATION |
| PAGE: 84 - Compensation Committee Interlocks and Insider Participation |
| PAGE: 85 - Stock Ownership of Certain Beneficial Owners |
| PAGE: 86 - PLAN OF DISTRIBUTION |
| PAGE: 87 - Notice to Investors in the United Kingdom |
| PAGE: 88 - European Economic Area |
| PAGE: 89 - Dividends, Voting Rights and Liquidation |
| PAGE: 90 - Transfer Agent and Registrar |
| PAGE: 91 - EXPERTS |
| PAGE: 92 - NOVADEL PHARMA INC. |
| PAGE: 93 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM |
| PAGE: 94 - NOVADEL PHARMA INC. |
| PAGE: 95 - NOVADEL PHARMA INC. |
| PAGE: 96 - NOVADEL PHARMA INC. |
| PAGE: 97 - NOVADEL PHARMA INC. |
| PAGE: 98 - NOVADEL PHARMA INC. |
| PAGE: 99 - NOVADEL PHARMA INC. |
| PAGE: 100 - NOVADEL PHARMA INC. |
| PAGE: 101 - NOVADEL PHARMA INC. |
| PAGE: 102 - NOVADEL PHARMA INC. |
| PAGE: 103 - NOVADEL PHARMA INC. |
| PAGE: 104 - NOVADEL PHARMA INC. |
| PAGE: 105 - NOVADEL PHARMA INC. |
| PAGE: 106 - NOVADEL PHARMA INC. |
| PAGE: 107 - NOVADEL PHARMA INC. |
| PAGE: 108 - NOVADEL PHARMA INC. |
| PAGE: 109 - NOVADEL PHARMA INC. |
| PAGE: 110 - NOVADEL PHARMA INC. |
| PAGE: 111 - NOVADEL PHARMA INC. |
| PAGE: 112 - NOVADEL PHARMA INC. |
| PAGE: 113 - NOVADEL PHARMA INC. |
| PAGE: 114 - NOVADEL PHARMA INC. |
| PAGE: 115 - NOVADEL PHARMA INC. |
| PAGE: 116 - NOVADEL PHARMA INC. |
| PAGE: 117 - NOVADEL PHARMA INC. |
| PAGE: 118 - NOVADEL PHARMA INC. |
| PAGE: 119 - NOVADEL PHARMA INC. |
| PAGE: 120 - NOVADEL PHARMA INC. |
| PAGE: 121 - NOVADEL PHARMA INC. |
| PAGE: 122 - NOVADEL PHARMA INC. |
| PAGE: 123 - NOVADEL PHARMA INC. |
| PAGE: 124 - NOVADEL PHARMA INC. |
| PAGE: 125 - NOVADEL PHARMA INC. |
| PAGE: 126 - NOVADEL PHARMA INC. |
| PAGE: 127 - NOVADEL PHARMA INC. |
| PAGE: 128 - NOVADEL PHARMA INC. |
| PAGE: 129 - NOVADEL PHARMA INC. |
| PAGE: 130 - 50,000,000 UNITS |
| PAGE: 131 - PART II |
| PAGE: 132 - |
| PAGE: 133 - Item 16. Exhibits and fFinancial Statement Schedules |
| PAGE: 134 - |
| PAGE: 135 - |
| PAGE: 136 - |
| PAGE: 137 - Item 17. Undertakings |
| PAGE: 138 - |
| PAGE: 139 - SIGNATURES |
| 3. EX-5.1 - Opinion regarding legality
|
| PAGE: 1 - Exhibit 5.1 |
| 4. EX-23.1 - Consents of experts and counsel
|
| PAGE: 1 - Exhibit 23.1 |
F 888.329.6696